ASCO 2015
Enzalutamide May Represent Novel Therapeutic Option for Triple-Negative Breast Cancer
June 02, 2015Enzalutamide may be a viable alternative therapy over cytotoxic chemotherapy for individuals with triple-negative breast cancer, according to a study presented at the 2015 American Society of Clinical Oncology annual meeting.
Persistent HPV16 in Oral Rinses Signals Poor Prognosis for HPV-Positive Oropharyngeal Carcinoma
June 02, 2015Detection of human papillomavirus (HPV)16 DNA in oral rinses following treatment for HPV-positive oropharyngeal carcinoma could be a potential tool for long-term tumor surveillance, a study concluded at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting.
Adapting Pediatric Cancer Treatments to Spur Early Detection and Reduce Late Effects
June 01, 2015Modifying pediatric cancer treatments may reduce occurrence of late effects and promoting early detection, indicated data from a 5-year analysis of childhood cancers survivors presented at ASCO 2015.
Radiosurgery and Careful Monitoring Combo Recommended for Newly Diagnosed Brain Metastases
June 01, 2015Radiosurgery and close monitoring is recommended to better preserve cognitive function in newly diagnosed brain metastases.
Elective Neck Dissection Recommended Standard of Care for Early Oral Cancer
June 01, 2015Elective neck dissection in clinically node-negative early oral squamous cell carcinoma should be considered the standard of care.
Nivolumab Yields Better Clinical Outcomes for Advanced Melanoma
June 01, 2015Treatment-naïve patients with advanced melanoma had significantly better clinical outcomes with nivolumab alone or in combination with ipilimumab.
PET-CT Surveillance Cost-Effective for Locally Advanced Head and Neck Squamous Cell Cancer
June 01, 2015PET-CT guided active surveillance for patients with locally advanced head and neck squamous cell cancer is an option over node dissection, per analysis data presented at the 2015 American Society of Clinical Oncology annual meeting.
Pembrolizumab Active in Advanced Gastric Cancer
June 01, 2015The anti-PD-1 monoclonal antibody, pembrolizumab (MK-3475), demonstrated promising antitumor activity in advanced gastric cancer, according to a study presented at the 2015 ASCO Annual Meeting.
Aspirin Exposure after Colorectal Cancer Diagnosis Associated with Improved Survival
June 01, 2015Aspirin exposure after a colorectal cancer diagnosis was independently associated with improved colorectal cancer-specific survival.
Nivolumab Demonstrates Consistent Adverse Event Profile for Recurrent Glioblastoma
May 31, 2015The adverse event profile of nivolumab with or without ipilimumab in patients with glioblastoma was encouraging.
Addition of SIRT Fails to Improve Overall Progression-free Survival in Colorectal Cancer Liver Metastases
May 31, 2015Addition of selective internal radiation therapy (SIRT) failed to improve progression-free survival in non-resectable colorectal cancer liver metastases.
Combination of mFOLFOX6 and Radiotherapy Yields Higher pCR in Rectal Cancer
May 31, 2015mFOLFOX6 administered concurrently with radiation therapy resulted in a higher pathological complete response in rectal cancer.
Higher Vitamin D Concentrations Associated with Improved Survival in mCRC
May 31, 2015In patients with metastatic colorectal cancer treated with chemotherapy plus biologics, increased vitamin D levels have been linked to improved survival, according to information presented at the ASCO 2015 Annual Meeting.
Narrow Excision Margins in High Risk Primary Melanoma Associated with Higher Cancer-Related Death
May 31, 2015Higher mortality is associated with more narrow margins for high-risk primary melanoma, per research presented at the American Society of Clinical Oncology (ASCO) 2015 Annual Meeting in Chicago.
RFA Plus Chemo Associated with Improved Survival in Unresectable Colorectal CA Liver Metastases
May 31, 2015A combination of radiofrequency ablation and systemic chemotherapy was associated with improved long-term overall survival in patients with unresectable colorectal cancer liver metastases, according to data presented at the 2015 American Society of Clinical Oncology annual meeting.
Internationally Applicable Prognostic Index for 5-Year OS Validated for Patients with CLL
May 31, 2015A new meta-analysis of 26 factors has resulted in an internationally applicable prognostic index for patients with chronic lymphocytic leukemia, according to study results presented at 2015 ASCO Annual Meeting.
Optimal Sequencing for Chemotherapy and Radium 223 for Prostate Cancer Under Debate
May 30, 2015When is chemotherapy or radium 223 the optimal treatment for men with advanced prostate cancer?
Removing the Obstacles Associated With Survivorship Care
May 30, 2015As of 2012 in the U.S. there were 14 million cancer survivors, a number that is expected to grow to 18 million by 2022.
MEDI4736 Shows Consistent Safety Response in Head and Neck Squamous Cell Carcinoma
May 30, 2015Safety profile of MEDI4736 in patients with squamous cell carcinoma of the head and neck is manageable.
Pembrolizumab and Ipilimumab Combo Safe for Melanoma and Renal Cell Carcinoma
May 30, 2015Pembrolizumab plus low-dose ipilimumab combination considered to have an acceptable safety profile in melanoma or renal cell carcinoma.
Ongoing Phase IIIb/IV Trial Shows Consistent Safety Data with Nivolumab in NSCLC
May 30, 2015Patients with advanced non-small cell lung cancer (NSCLC) treated with nivolumab demonstrated tolerability consistent with prior trails, according to data from a phase IIIb/IV trial presented at the 2015 American Society of Clinical Oncology (ASCO) annual meeting.
Diagnostic Assay Improves Outcomes Prediction in Early Breast Cancer, Nixing Need for Chemo
May 30, 2015Outcome prediction for postmenopausal patients with node-positive HR+ early breast cancer can be improved using a diagnostic assay, potentially negating the need for adjuvant chemotherapy, according to a study presented at ASCO 2015.
Letrozole Significantly Reduces Late Invasive Events in HR+ Early Breast Cancer
May 30, 2015Letrozole significantly reduced the rate of late invasive breast cancer events in postmenopausal women who had completed 4+ years of adjuvant endocrine therapy for HR+ breast cancer, the LATER trial concluded at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting.
Young Women with Breast Cancer on Ovarian Suppression Need Early Intervention to Mitigate Poor QOL
May 30, 2015Early intervention should be offered to young women with breast cancer on ovarian function suppression and tamoxifen, who experience poorer quality of life (QOL) in the early survivorship period, according to a study presented at the 2015 American Society of Clinical Oncology Annual Meeting.
Sign Up for Free e-newsletters
ONA Articles
- Triplet Regimen Found Most Effective for Relapsed/Refractory Multiple Myeloma
- Integrating Preoperative Oral Care Into Cancer Treatment Plans
- Current Status and Dilemma of Second-line Treatment in Advanced Pancreatic Cancer: Is There a Silver Lining?
- American Association for Cancer Research Releases Its 2018 Annual Report
- Pulmonary Toxicity Increased in Pediatric Hodgkin Lymphoma Treated With Brentuximab Vedotin
- Benefit of Chemotherapy for Breast Cancer Observed With Midrange Gene Assay Score
- Antioxidant Interaction With Cancer Therapy
- Young Survivors of Breast Cancer Report Sexual Quality of Life Declines After Treatment
- Myeloablative Conditioning Effective in AML Secondary to MDS/MPN Prior to Allogeneic HCT
- Insurance Status Influences Overall Survival in Follicular Lymphoma
- Skin Cancer Screening: Are They Effective?
- Metronidazole, Vancomycin Recommended for C Difficile in Pediatric Oncology, HSCT
- CDC: HPV Vaccination Rates on the Rise Among Adolescents
- High-Dose vs Standard-Dose Flu Vaccine in Elderly Receiving Chemotherapy
- FDA Grants Approval to Novel Treatment for Hairy Cell Leukemia
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
| Bone Cancer | Regimens | Drugs |
| Brain Cancer | Regimens | Drugs |
| Breast Cancer | Regimens | Drugs |
| Endocrine Cancer | Regimens | Drugs |
| Gastrointestinal Cancer | Regimens | Drugs |
| Genitourinary Cancer | Regimens | Drugs |
| Gynecologic Cancer | Regimens | Drugs |
| Head and Neck Cancer | Regimens | Drugs |
| Hematologic Cancer | Regimens | Drugs |
| Lung Cancer | Regimens | Drugs |
| Other Cancers | Regimens | |
| Rare Cancers | Regimens | |
| Skin Cancer | Regimens | Drugs |